Ischemic heart disease is the largest single cause of death in the Western World, including one million heart attacks in the US every year with 20% deaths within one year. Post myocardial infarction (MI), there is currently no treatment to regenerate the injured heart muscle, and the permanent damage results in scar tissue and deterioration of the heart function, eventually leading to heart failure.

​

​Our innovative approach aims to restore the heart's inherent regenerative capabilities by rewiring tissue metabolism. The company’s initial focus is on the development of a new small molecule product candidate, MTX-101, based on a groundbreaking discovery from the company’s founder, Dr. Ahmed Mahmoud (Sanford Burnham Prebys), that stimulates the repair of damaged heart tissue, providing new hope for millions affected by cardiovascular disease. 

​​

​